{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:18:40Z","timestamp":1788200320648,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jogoh.2019.101643","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T17:49:55Z","timestamp":1569520195000},"page":"101643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study"],"prefix":"10.1016","volume":"49","author":[{"given":"Ruzanna","family":"Tshzmachyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Hambartsoumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogoh.2019.101643_bib0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogoh.2019.101643_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bpobgyn.2016.08.001","article-title":"Ovulation induction in polycystic ovary syndrome: Current options","volume":"37","author":"Legro","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/jhrs.JHRS_15_16","article-title":"Serum AMH level to predict the hyper response in women with PCOS and non-PCOS undergoing controlled ovarian stimulation in ART","volume":"10","author":"Vembu","year":"2017","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.jogoh.2019.101643_bib0020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0015-0282(02)03225-9","article-title":"A randomized controlled trial of laparoscopic ovarian diathermy vs. gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome","volume":"78","author":"Farquhar","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogoh.2019.101643_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/14647270802621358","article-title":"Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF","volume":"12","author":"Artini","year":"2009","journal-title":"Hum Fertil (Camb)"},{"key":"10.1016\/j.jogoh.2019.101643_bib0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/14647273.2011.608464","article-title":"Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles","volume":"14","author":"Tolikas","year":"2011","journal-title":"Hum Fertil (Camb)"},{"key":"10.1016\/j.jogoh.2019.101643_bib0035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/09513590.2013.777415","article-title":"The role of serum anti-Mullerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome","volume":"29","author":"Casadei","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12978-015-0053-4","article-title":"Optimal cutoff value of basal anti-mullerian hormone in iranian infertile women for prediction of ovarian hyper-stimulation syndrome and poor response to stimulation","volume":"12","author":"Aghass","year":"2015","journal-title":"Reprod Health"},{"key":"10.1016\/j.jogoh.2019.101643_bib0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/09513590.2017.1391206","article-title":"Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation","volume":"34","author":"Dahan","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/09513590.2015.1025379","article-title":"Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome","volume":"31","author":"Fusi","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/14647273.2013.795385","article-title":"Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical practice. Produced on behalf of the BFS Policy and Practice Committee","volume":"16","author":"Nardo","year":"2013","journal-title":"Hum Fertil (Camb)"},{"key":"10.1016\/j.jogoh.2019.101643_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/514159","article-title":"Prevention of Ovarian Hyperstimulation Syndrome: A Review","volume":"2015","author":"Smith","year":"2015","journal-title":"Obstet Gynecol Int"},{"issue":"1","key":"10.1016\/j.jogoh.2019.101643_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajog.2016.08.018","article-title":"Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial","volume":"216","author":"Mai","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0070","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.fertnstert.2017.08.017","article-title":"In vitro fertilization treatments with the use of clomiphene citrate or letrozole","volume":"108","author":"Haas","year":"2017","journal-title":"Fertil Steril"},{"issue":"February","key":"10.1016\/j.jogoh.2019.101643_bib0075","article-title":"Aromatase inhibitors for subfertile women with polycystic ovary syndrome","volume":"24","author":"Franik","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"May (1)","key":"10.1016\/j.jogoh.2019.101643_bib0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12958-018-0367-5","article-title":"The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle","volume":"16","author":"Haas","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogoh.2019.101643_bib0090","series-title":"Green-top guideline No. 5","author":"Ovarian Hyperstimulation Syndrome, Management","year":"2016"},{"key":"10.1016\/j.jogoh.2019.101643_bib0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0015-0282(00)01705-2","article-title":"Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate","volume":"75","author":"Mitwally","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogoh.2019.101643_bib0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/GRF.0b013e3182353d0f","article-title":"Use of aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome","volume":"4","author":"Casper","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00404-011-1951-5","article-title":"A randomized trial of ovulation induction with two different doses of Letrozole in women with PCOS","volume":"284","author":"Ramezanzadeh","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jogoh.2019.101643_bib0110","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/09513590.2017.1332174","article-title":"Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial","volume":"33","author":"Liu","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0115","doi-asserted-by":"crossref","first-page":"j138","DOI":"10.1136\/bmj.j138","article-title":"Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis","volume":"356","author":"Wang","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jogoh.2019.101643_bib0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12958-017-0288-8","article-title":"Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome?","volume":"15","author":"Haas","year":"2017","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0125","article-title":"Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation","volume":"11","author":"Kamath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jogoh.2019.101643_bib0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7827-3-54","article-title":"The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment","volume":"3","author":"Mitwally","year":"2005","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0135","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/humrep\/del273","article-title":"Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation","volume":"21","author":"Bedaiwy","year":"2006","journal-title":"Hum Reprod"},{"issue":"June (24)","key":"10.1016\/j.jogoh.2019.101643_bib0140","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.12659\/MSM.910743","article-title":"A retrospective study of letrozole treatment prior to human chorionic gonadotropin in women with polycystic ovary syndrome undergoing in vitro fertilization at risk of ovarian hyperstimulation syndrome","volume":"20","author":"Chen","year":"2018","journal-title":"Med Sci Monit"},{"issue":"4","key":"10.1016\/j.jogoh.2019.101643_bib0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humrep\/deg166","article-title":"Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos","volume":"18","author":"Orvieto","year":"2003","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.jogoh.2019.101643_bib0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/humupd\/dmn008","article-title":"Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome","volume":"14","author":"Soares","year":"2008","journal-title":"Hum Reprod Update"},{"issue":"5","key":"10.1016\/j.jogoh.2019.101643_bib0155","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00404-015-3987-4","article-title":"Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome","volume":"293","author":"\u015eahin","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"June (2)","key":"10.1016\/j.jogoh.2019.101643_bib0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.repbio.2016.04.001","article-title":"Segmented ART - The new era in ART?","volume":"16","author":"Ozgur","year":"2016","journal-title":"Reprod Biol"},{"issue":"July (2)","key":"10.1016\/j.jogoh.2019.101643_bib0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogoh.2019.101643_bib0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.fertnstert.2006.01.046","article-title":"Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures","volume":"86","author":"Asimakopoulos","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogoh.2019.101643_bib0175","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.fertnstert.2011.01.163","volume":"95","author":"Griesinger","year":"2011","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.jogoh.2019.101643_bib0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.repbio.2017.12.004","article-title":"Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome","volume":"18","author":"Zech","year":"2017","journal-title":"Reprod Biol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0185","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10815-011-9627-4","article-title":"Serum anti-M\u00fcllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles","volume":"28","author":"Ocal","year":"2011","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.jogoh.2019.101643_bib0190","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1080\/09513590.2017.1320385","article-title":"Effectiveness of mild ovarian stimulation versus GnRH agonist protocol in women undergoing assisted reproductive technology: a meta-analysis","volume":"33","author":"Fan","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0195","first-page":"1","article-title":"Low dose HP-hMG in an antagonist protocol for IVF in ovulatory and anovulatory patients with high AMH","volume":"18","author":"Sopa","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/ajo.12406","article-title":"Consensus statement on prevention and detection of ovarian hyperstimulation syndrome","volume":"55","author":"Boothroyd","year":"2015","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jogoh.2019.101643_bib0205","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/humrep\/deg311","article-title":"Aromatase inhibition reduces gonadotropin dose required for controlled ovarian stimulation in women with unexplained infertility","volume":"18","author":"Mitwally","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogoh.2019.101643_bib0210","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00404-018-4688-6","article-title":"Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials","volume":"297","author":"Hu","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jogoh.2019.101643_bib0215","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/09513590.2017.1318370","article-title":"Clinical utility of different anti-M\u00fcllerian hormone \u2013 AMH assays for the purpose of pregnancy prediction","volume":"10","author":"Liss","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.jogoh.2019.101643_bib0220","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.fertnstert.2005.01.117","article-title":"The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study","volume":"84","author":"Garcia-Velasco","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogoh.2019.101643_bib0225","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.fertnstert.2006.03.014","article-title":"Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate","volume":"85","author":"Tulandi","year":"2006","journal-title":"Fertil Steril"}],"container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468784719300686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468784719300686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:40:09Z","timestamp":1764016809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468784719300686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2468784719300686"],"URL":"https:\/\/doi.org\/10.1016\/j.jogoh.2019.101643","relation":{},"ISSN":["2468-7847"],"issn-type":[{"value":"2468-7847","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Gynecology Obstetrics and Human Reproduction","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogoh.2019.101643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101643"}}